AzTrials
AzTrials

Breast - FemaleNCT07804147

Evaluation and Reclassification of ( BI-RADS 3) Breast Lesions in Dense Breast

An observational study of Breast - Female and Dense Breast Parenchyma, run by Sohag University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

This prospective study aims to compare combined breast ultrasound (US) and digital mammography (DM) with digital breast tomosynthesis (DBT) in the evaluation and reclassification of BI-RADS 3 (probably benign) breast lesions. Read more about this study

Who is it for?
Any age, women only
How many people
30 participants
Where
1 siteEgypt
Study dates
12 Jul 2026to 1 Feb 2027
How long will I take part?
6 Months
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The study population will consist of 30 female patients presenting with at least one non-calcified breast lesion initially classified as BI-RADS 3 (probably benign) on standard 2D digital mammography. Patients with breast densities B, C, or D will be included, with particular consideration of dense breasts (C and D). All eligible participants will undergo complementary targeted breast ultrasound and digital breast tomosynthesis for lesion evaluation and BI-RADS reclassification.

Who may be able to join

  • - Radiological classification: Patients with at least one non-calcified breast lesion initially classified as BI-RADS 3 (probably benign) on standard 2D digital mammography.
  • - Breast density: Patients with breast densities B, C, or D are eligible, with particular consideration of dense breasts (C and D).

Who cannot join

  • Suspicious imaging features:
  • Patients with any lesion demonstrating BI-RADS 4 or 5 characteristics, including spiculated margins, fine linear branching calcifications, or architectural distortion.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Faculty of Medicine Sohag University

    Sohag, Sohag Governorate, 0000

Other trials in Egypt

About this study

Official title: Combined Ultrasound and Digital Mammography Versus Digital Breast Tomosynthesis in the Evaluation and Reclassification of ( BI-RADS 3) Breast Lesions in Dense Breast

This prospective study aims to compare combined breast ultrasound (US) and digital mammography (DM) with digital breast tomosynthesis (DBT) in the evaluation and reclassification of BI-RADS 3 (probably benign) breast lesions. The study will include 30 female patients with non-calcified breast lesions initially classified as BI-RADS 3 on digital mammography. Patients will undergo complementary targeted breast ultrasound and DBT. The imaging findings will be assessed separately and then integrated to determine the final BI-RADS classification. The study will evaluate whether DBT and combined US with DM can improve characterization and reclassification of BI-RADS 3 lesions, potentially reducing unnecessary short-interval follow-up while identifying lesions requiring further assessment.

Read the detailed description

BI-RADS category 3 lesions are considered probably benign findings but generally require short-interval imaging follow-up to document stability. This may result in additional examinations and patient anxiety. The study will investigate the role of digital breast tomosynthesis (DBT) compared with combined ultrasound (US) and digital mammography (DM) in the assessment and reclassification of these lesions, particularly in patients with dense breast tissue.

This is a prospective study to be conducted at Sohag University Hospital. The study population will consist of 30 female patients presenting with at least one non-calcified breast lesion initially classified as BI-RADS 3 on standard 2D digital mammography. Patients with breast densities B, C, or D will be eligible, with particular consideration of dense breasts (C and D).

All patients will undergo baseline 2D digital mammography, followed by complementary targeted breast ultrasound using a high-resolution linear-array transducer. Ultrasound assessment will include evaluation of lesion shape, orientation, margins, echo pattern, and posterior acoustic features, with a separate US-based BI-RADS assessment.

Patients will also undergo digital breast tomosynthesis using standard bilateral craniocaudal and mediolateral oblique views, with reconstruction into 1-mm slices. DBT assessment will include evaluation of lesion margins and assessment for associated architectural distortion or microcalcifications that may not be apparent on 2D mammography. A separate DBT-based BI-RADS assessment will be assigned.

The imaging findings will subsequently undergo an integrated assessment. The protocol includes independent assessment of US and DBT findings followed by assignment of a final BI-RADS category based on the combined findings. Reclassification may include downgrading a finding when DBT demonstrates that an apparent mammographic asymmetry represents overlapping normal breast tissue, or upgrading a lesion when suspicious ultrasound features such as non-parallel orientation or angular margins are identified.

Diagnostic performance measures, including sensitivity, specificity, positive predictive value, and negative predictive value, will be calculated for US and DBT. Data will be analyzed using SPSS software.

Keywords
breast, dense breast, probably benign breast lesions, BIRADs 3, breast lesions reassessment

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07804147
Study groupRoleWhat they receive
BI-RADS 3 Breast Lesion CohortFemale patients with at least one non-calcified breast lesion initially classified as BI-RADS 3 (probably benign) on digital mammography. Participants undergo complementary targeted breast ultrasound and digital breast tomosynthesis for evaluation and reclassification of the lesion.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in BI-RADS classification of breast lesions

    The proportion of initially BI-RADS 3 breast lesions that are reclassified following assessment with digital breast tomosynthesis and complementary breast ultrasound, including downgrading to BI-RADS 2 or upgrading to a higher BI-RADS category based on imaging findings.

    Measured: through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2026
  2. Study start12 Jul 2026
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion1 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (actual)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07804147
Sponsor's protocol ID
Soh-Med-26-7-16MS
Status last verified
Sep 2026
First submitted
27 Aug 2026
Last updated
4 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared because no individual participant data sharing plan has been established for this study. Study data will be used for the purposes of the research and statistical analysis described in the study protocol.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in